Tech Center 1600 • Art Units: 1675
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17692755 | IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS | Non-Final OA | Xencor, Inc. |
| 17849075 | METHODS AND COMPOSITIONS FOR INHIBITING P97 | Final Rejection | California Institute of Technology |
| 17786375 | INTERLEUKIN-2 IN COMBINATION WITH TNF RECEPTOR FAMILY MEMBERS FOR THE EXPANSION OF T-REGULATORY CELLS | Final Rejection | AMGEN INC. |
| 19289532 | CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS | Final Rejection | MERCK SERONO SA |
| 17769722 | NEONATAL FC RECEPTOR BINDING AFFIMERS | Final Rejection | LG CHEM, LTD. |
| 17872225 | METHODS FOR TREATING CHRONIC SPONTANEOUS URTICARIA BY ADMINISTERING AN IL-4R ANTAGONIST | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 19237968 | DUAL CSF1-IL-10 CYTOKINE | Final Rejection | FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA |
| 17419870 | HARNESSING INFLAMMATION TO TREAT NEURODEVELOPMENTAL DISORDERS | Final Rejection | Massachusetts Institute of Technology |
| 17920503 | STRUCTURALLY-STABILIZED AND HDMX-SELECTIVE P53 PEPTIDES AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17774298 | HLA RESTRICTED HORMAD1 T CELL RECEPTORS AND USES THEREOF | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17764104 | IMMUNOGENIC EGFR PEPTIDE COMPOSITIONS AND THEIR USE IN THE TREATMENT OF CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 17635760 | CIRCULAR RNA MODIFICATION AND METHODS OF USE | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17622504 | METHODS AND MATERIALS FOR TARGETED EXPANSION OF REGULATORY T CELLS | Non-Final OA | The Johns Hopkins University |
| 17769642 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | Non-Final OA | Yale University |
| 18302630 | METHOD OF CREATING HUMAN PLURIPOTENT STEM CELL DERIVED BRAIN PERICYTE-LIKE CELLS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17799503 | NOVEL T CELL RECEPTORS (TCRS) THAT REACT TO NEOANTIGENS | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17210454 | COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE AND BACTERIAL INFECTION | Final Rejection | Prince Biotech, LLC |
| 17906467 | MULTIVALENT CHEMOKINE RECEPTOR BINDING COMPLEXES | Non-Final OA | CITY OF HOPE |
| 17870024 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CEA AND ANTI-CEA-IL2 IMMUNOCYTOKINES FOR CANCER THERAPY | Non-Final OA | City of Hope |
| 17635625 | TGF-beta TRAP | Final Rejection | NANTBIO, INC. |
| 17442568 | TREATMENT INVOLVING INTERLEUKIN-2 (IL2) AND INTERFERON (IFN) | Final Rejection | TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
| 17914261 | MASKED IL12 FUSION PROTEINS AND METHODS OF USE THEREOF | Non-Final OA | Zymeworks BC Inc. |
| 17926673 | IMPROVED GRANZYME B VARIANT | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17599921 | Fc-MODIFIED BIOLOGICALS FOR LOCAL DELIVERY TO COMPARTMENT, IN PARTICULAR TO THE CNS | Non-Final OA | Universität Zürich |
| 17763973 | STING AGONIST COMPRISING EXOSOMES COMBINED WITH IL-12 DISPLAYING EXOSOMES FOR TREATING A TUMOUR | Final Rejection | LONZA SALES AG |
| 18002613 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | Non-Final OA | Inhibrx Biosciences, Inc. |
| 17798774 | TISSUE TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS | Non-Final OA | PANDION OPERATIONS, INC. |
| 17777088 | INTERLEUKIN 15 FUSION PROTEINS AND PRODRUGS, AND COMPOSITIONS AND METHODS THEREOF | Non-Final OA | IMMUNE TARGETING INC. |
| 17911922 | INTERLEUKIN-2 MUTANT AND USE THEREOF | Non-Final OA | FORTVITA BIOLOGICS (SINGAPORE) PTE. LTD. |
| 17490516 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Final Rejection | Cue Biopharma, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy